Cardium Therapeutics is implementing a broad-based strategy of engaging the medical and health marketplace, focused on opportunities offering a clear path to monetization. Generx, Cardium’s lead clinical development product candidate, is unique in its ability to stimulate the growth of … Continue reading →

Today before the bell, Cardium Therapeutics announced that it has received ISO 13485:2003 certification for its Excellagen® advanced wound care product by BSI, one of the world’s leading certification bodies. This certification is a stand-alone standard developed by the International … Continue reading →

Earlier today, Cardium Therapeutics announced that its To Go Brands® division has expanded its VitaRocks® kids vitamins product line and that retail distribution of the newly-designed products is being been expanded to include select Target stores. The VitaRocks products are … Continue reading →

Coronary artery disease – the No. 1 cause of death worldwide – kills more than 17 million people around the world each year. It’s easy to skim over the statistics when “death” dominates global headlines. We are desensitized to a … Continue reading →

Cardium Therapeutics’ lead clinical development product candidate is Generx, a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. Unlike other coronary drug therapeutics, Generx is designed to actually stimulate the … Continue reading →

Today before the opening bell, Cardium Therapeutics announced that the American Podiatric Medical Association (APMA) has granted its prestigious Seal of Approval to Excellagen®, Cardium’s advanced, FDA-cleared wound care product, for improving foot health and mobility. Excellagen is a syringe-based, … Continue reading →

Cardium Therapeutics has a capital-efficient, asset-based business strategy focused on building a diversified portfolio of new and innovative bio-medical product opportunities and businesses, leveraging research and development investments by big pharma, venture, and institutional investors. A key component to that … Continue reading →

Today before the opening bell, Cardium Therapeutics announced its Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D. delivered a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The presentation, titled “Optimizing Phase III Trial … Continue reading →

Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative health products. As an important part of its overall strategy, the company has entered the health and wellness market through the … Continue reading →

One of the challenges of every parent is ensuring that their children get the kind of nutrition they need. You can avoid keeping junk foods around the house, and make a point of serving vegetables and fruit with every meal, … Continue reading →